KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Esperion Therapeutics (ESPR) Long-Term Deferred Tax (2016 - 2017)

Esperion Therapeutics filings provide 1 years of Long-Term Deferred Tax readings, the most recent being $99.8 million for Q4 2017.

On a quarterly basis, Long-Term Deferred Tax changed N/A to $99.8 million in Q4 2017 year-over-year; TTM through Dec 2017 was $99.8 million, a N/A change, with the full-year FY2017 number at $99.8 million, changed N/A from a year prior.
Long-Term Deferred Tax hit $99.8 million in Q4 2017 for Esperion Therapeutics.
In the past five years, Long-Term Deferred Tax ranged from a high of $99.8 million in Q4 2017 to a low of $99.8 million in Q4 2017.